All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Visual abstract | Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia

Jun 17, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL

The ALL Hub is pleased to present a visual abstract representing key data from the phase II ITCC-059 trial evaluating inotuzumab ozogamicin as single agent in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.



Visual abstract

To download this visual abstract, click below.

Download here

Share: